Krystal Biotech Inc. (KRYS)
KRYS Reports Positive Early Data for KB113 in Gorlin Syndrome
Krystal Biotech reports promising early results for KB113, with tumor regression seen in more than 80% of assessed lesions in an early Gorlin syndrome study.
Krystal Biotech: My Analysis Suggests Stock Has Not Yet Reached Peak Value
Krystal Biotech is rated a 'Buy' due to strong Vyjuvek sales, robust profitability, and a promising pipeline. Vyjuvek, approved for DEB, is on track for blockbuster status in my view with $119.2m Q2 revenue and expanding global reach. KRYS maintains a $1.1bn cash position, a 40% operating margin, and trades at ~12x forward P/E, supporting attractive valuation.
Krystal Stock Gains 13.4% in a Month: What Is Driving the Rally?
KRYS' Vyjuvek growth and expanding genetic medicine pipeline boost investor confidence as the company advances toward multi-product growth.
Krystal Biotech (KRYS) Up 12% Since Last Earnings Report: Can It Continue?
Krystal Biotech (KRYS) reported earnings 30 days ago. What's next for the stock?
Krystal Q2 Earnings & Sales Beat Estimates, Pipeline in Focus
KRYS tops Q2 EPS estimates as Vyjuvek sales climb 24%, but its shares fall despite broader access, global expansion and pipeline progress.
Krystal Biotech Q2 Earnings Call Highlights
Krystal Biotech NASDAQ: KRYS reported second-quarter 2026 net revenue of $119.2 million from global sales of VYJUVEK, up 24% from $96 million in the prior-year period, as the company expanded treatment access for patients with dystrophic epidermolysis bullosa, or DEB, in the United States and overseas.
Krystal Biotech, Inc. (KRYS) Q2 Earnings and Revenues Beat Estimates
Krystal Biotech, Inc. (KRYS) came out with quarterly earnings of $1.79 per share, beating the Zacks Consensus Estimate of $1.7 per share. This compares to earnings of $1.29 per share a year ago.
Krystal Biotech: International Expansion And A Vibrant Pipeline
Krystal Biotech (KRYS) earns a STRONG BUY rating, driven by its fortress-like balance sheet, exceptional margins, and rapid Vyjuvek commercial success. KRYS's international Vyjuvek launches in Europe and Japan are accelerating topline growth, with further expansion into Italy, Spain, and the UK expected to boost revenues. KRYS's pipeline, leveraging its proprietary HSV-1 platform, spans respiratory, ophthalmology, oncology, and aesthetics, reducing future reliance on Vyjuvek.
Krystal Biotech: Profitable, Self-Funding, And Loaded With Optionality
Krystal Biotech remains a Buy as VYJUVEK drives profitability and its HSV-1 platform underpins a robust pipeline. Q1 results highlight operating leverage: $116.4M VYJUVEK revenue, $56M net income, and self-funded R&D with a $1B cash position. Upcoming catalysts include registrational data for KB803 and KB801, with KB801 positioned as a potential blockbuster in rare ophthalmology.
Krystal Biotech, Inc. (KRYS) Earnings Expected to Grow: Should You Buy?
Krystal Biotech (KRYS) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Krystal Biotech (KRYS) Soars 3.4%: Is Further Upside Left in the Stock?
Krystal Biotech (KRYS) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.
Is the Options Market Predicting a Spike in Krystal Biotech Stock?
Investors need to pay close attention to KRYS stock based on the movements in the options market lately.
